Merck has received approval from China's National Medical Products Administration for a subcutaneous injection version of pembrolizumab, covering 19 solid tumor indications and marking the first such approval for a PD-1 inhibitor in the country.
- First PD-1 inhibitor subcutaneous injection approved in China
- Covers 19 solid tumor indications for pembrolizumab
- Could improve treatment convenience and hospital resource use
Why it matters
China faces a rising cancer burden, making efficient and patient-friendly therapeutic options increasingly important. Subcutaneous injection typically requires less administration time and healthcare resources than intravenous infusion, potentially improving clinical workflow and patient experience.
By diversifying administration routes, Merck aims to expand pembrolizumab’s usability across various clinical settings and patient conditions. This innovation aligns with ongoing efforts to optimize cancer care delivery in China, addressing both physician and patient demands for more convenient immunotherapy options.
What to watch next
Market uptake of the subcutaneous pembrolizumab will be a key indicator of its impact on treatment paradigms in China’s oncology landscape. Clinicians and healthcare institutions will assess how this formulation can complement or replace intravenous dosing in routine practice.